Search research articles
Contact Us
Filters
Showing results (61-70 of 68) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 68 results.
Blood Neoplasia
|
June 2, 2025
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Paul G Kemps, F J Sherida H Woei-A-Jin, Patrick Schöffski, et al.
Frontiers in Immunology
|
January 31, 2020
Apparent Lack of <i>BRAF</i><sup></sup> Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8<sup>+</sup> T Cells in Langerhans Cell Histiocytosis
Paul G Kemps, Timo C Zondag, Eline C Steenwijk, et al.
Blood
|
September 24, 2024
Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue
Paul G Kemps, Hans J Baelde, Ruben H P Vorderman, et al.
Blood Advances
|
September 9, 2022
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
Paul G Kemps, Timo C E Zondag, Helga B Arnardóttir, et al.
Hemasphere
|
June 9, 2026
Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis
Francesco Pegoraro, Francois Chalard, Dmitry Evseev, et al.
Blood
|
August 18, 2023
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Aldo A Acosta-Medina, Paul G Kemps, Timo C E Zondag, et al.
Blood Advances
|
February 12, 2026
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients
Jean Donadieu, Dmitry Evseev, Francesco Pegoraro, et al.
Blood
|
November 2, 2021
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Paul G Kemps, Jennifer Picarsic, Benjamin H Durham, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 68) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 68 results.
Blood Neoplasia
|
June 2, 2025
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Paul G Kemps, F J Sherida H Woei-A-Jin, Patrick Schöffski, et al.
Frontiers in Immunology
|
January 31, 2020
Apparent Lack of <i>BRAF</i><sup></sup> Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8<sup>+</sup> T Cells in Langerhans Cell Histiocytosis
Paul G Kemps, Timo C Zondag, Eline C Steenwijk, et al.
Blood
|
September 24, 2024
Recurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissue
Paul G Kemps, Hans J Baelde, Ruben H P Vorderman, et al.
Blood Advances
|
September 9, 2022
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
Paul G Kemps, Timo C E Zondag, Helga B Arnardóttir, et al.
Hemasphere
|
June 9, 2026
Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis
Francesco Pegoraro, Francois Chalard, Dmitry Evseev, et al.
Blood
|
August 18, 2023
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Aldo A Acosta-Medina, Paul G Kemps, Timo C E Zondag, et al.
Blood Advances
|
February 12, 2026
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients
Jean Donadieu, Dmitry Evseev, Francesco Pegoraro, et al.
Blood
|
November 2, 2021
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Paul G Kemps, Jennifer Picarsic, Benjamin H Durham, et al.
Page
of 7